


# Reference Data

(Consolidated Financial Results for Q1 FY2022)



Daiichi-Sankyo

July 29, 2022

Daiichi Sankyo Co., Ltd.

<https://www.daiichisankyo.com>

# Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Sheet to adjust Operating Profit to Core Operating Profit	P2
3.	Revenue of Global Products	P3
4.	Revenue by Business Units and Products	P5
5.	Consolidated Statement of Financial Position	P8
6.	Consolidated Statement of Cash Flows	P10
7.	Number of Employees	P11
8.	Capital Expenditure, Depreciation and Amortization	P11
9.	Summary of Product Outlines	P12
10.	Quarterly Data	P13
11.	Historical Data	P18
12.	Major R&D Pipeline (Innovative pharmaceuticals)	P22

# 1. Consolidated Statement of Profit or Loss

JPY Bn	FY2021Q1		FY2022Q1					FY2022			
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast	YoY	YoY (%)
<b>Revenue</b>	100.0%	264.1	100.0%	280.3	24.4%	16.2	+6.2%	100.0%	1,150.0	105.1	+10.1%
Cost of sales*1	32.2%	85.2	26.6%	74.7	22.8%	-10.5	-12.3%	28.5%	328.0	-20.0	-5.8%
Gross Profit	67.8%	178.9	73.4%	205.6	25.0%	26.7	+14.9%	71.5%	822.0	125.1	+18.0%
SG&A expenses*1	30.8%	81.2	34.4%	96.3	23.5%	15.1	+18.6%	35.7%	410.0	57.9	+16.4%
R&D expenses*1	20.5%	54.0	26.7%	74.9	24.4%	20.9	+38.7%	26.7%	307.0	52.9	+20.8%
<b>Core Operating Profit</b>	16.5%	43.7	12.3%	34.4	32.7%	-9.3	-21.3%	9.1%	105.0	14.4	+15.9%
Temporary income*2		2.1		0.0		-2.1			-	-3.9	
Temporary expenses*2		0.0		-		-0.0			-	-21.5	
<b>Operating Profit</b>	17.3%	45.8	12.3%	34.4	32.7%	-11.4	-24.9%	9.1%	105.0	32.0	+43.8%
Financial income/expenses		1.3		-4.9		-6.2					
Share of profit or loss of investments accounted for using the equity method		-0.0		-0.0		-0.0					
<b>Profit before tax</b>	17.8%	47.1	10.5%	29.4	28.0%	-17.6	-37.5%	9.1%	105.0	31.5	+42.8%
Income taxes		11.8		10.6		-1.3					
<b>Profit for the year</b>	13.3%	35.2	6.7%	18.9	22.7%	-16.4	-46.5%	7.2%	83.0	16.0	+23.9%
<b>Profit attributable to owners of the Company</b>	13.3%	35.2	6.7%	18.9	22.7%	-16.4	-46.5%	7.2%	83.0	16.0	+23.9%
Tax rate		25.2%		35.9%							
Overseas sales ratio		44.7%		55.4%							
Currency Rate (Average)											
USD/JPY		109.49		129.57					130.00		
EUR/JPY		131.95		138.10					140.00		

Forex impact: +17.3  
(USD: +11.5, EUR: +1.9, ASCA: +3.8)

Forex impact: +3.7  
(USD: +3.6, EUR: -0.0, ASCA: +0.1)

Forex impact: +7.2  
(USD: +5.4, EUR: +0.5, ASCA: +1.3)

Forex impact: +6.5  
(USD: +6.1, EUR: +0.4, ASCA: +0.1)

Forex impact: -0.2  
(USD: -3.5, EUR: +1.0, ASCA: +2.3)

- Deterioration in forex gains/losses -3.2  
- Deterioration in investment securities valuation gains / losses -2.8

## Annual impact of one yen change

	Forecast	
	USD	EUR
Revenue	2.5 JPY Bn	1.2 JPY Bn
Operating Profit	-0.5 JPY Bn	0.3 JPY Bn

\*This report is not subject to audit procedures.

※1 Temporary income and expenses are excluded for cost of sales, SG&A expenses and R&D expenses

※2 See page 2 for the definition of temporary income and expenses and the adjustment of operating profit and core operating profit

## 2. Sheet to adjust Operating Profit to Core Operating Profit

### FY2021Q1 Results

JPY Bn	Full base	Adjustment					Core base
		gains and losses related to sale of fixed assets	gains and losses related to restructuring	gains and losses related to impairment,	gains and losses related to loss compensation, reconciliation	Others	
<b>Revenue</b>	<b>264.1</b>						<b>264.1</b>
Cost of sales	85.2					-0.1	85.2
SG&A expenses	81.3					-0.0	81.2
R&D expenses	54.0					-0.0	54.0
Other income*	2.2	-2.1				-0.1	-
Other expenses*	0.0	-0.0					-
<b>Core Operating Profit**</b>							<b>43.7</b>
Temporary income		2.1 <sup>*1</sup>				0.0	2.1
Temporary expenses		0.0					0.0
<b>Operating Profit (full)</b>	<b>45.8</b>						<b>45.8</b>

<Major Temporary income and Temporary expenses>

<sup>\*1</sup> Gains related to sale of fixed assets of Osaka logistics center

### FY2022Q1 Results

JPY Bn	Full base	Adjustment					Core base
		gains and losses related to sale of fixed assets	gains and losses related to restructuring	gains and losses related to impairment,	gains and losses related to loss compensation, reconciliation	Others	
<b>Revenue</b>	<b>280.3</b>						<b>280.3</b>
Cost of sales	74.8					-0.1	74.7
SG&A expenses	96.4					-0.0	96.3
R&D expenses	74.9					-0.0	74.9
Other income*	0.2	-0.0				-0.2	-
Other expenses*	-						-
<b>Core Operating Profit**</b>							<b>34.4</b>
Temporary income		0.0					0.0
Temporary expenses							-
<b>Operating Profit (full)</b>	<b>34.4</b>						<b>34.4</b>

<Major Temporary income and Temporary expenses>

\* The Company discloses profit and loss for which the offsetting of income and expenses is not permitted as Other income and Other expenses in the consolidated statement of income on a full basis (IFRS standards) from the current fiscal year. Profit and loss from the sale of assets, etc. are included in this Other income and Other expenses.

\*\* As an indicator of ordinary profitability, "core operating profit" which excludes temporary income and expenses from operating income is disclosed. Gains and losses related to: sale of fixed assets, restructuring (excluding the sales of pipeline and launched products), impairment, loss compensation, reconciliation, and other non-temporary and material gains and losses are included in the "temporary income and expenses".

### 3. Revenue of Global Products (1)

JPY Bn		FY2021 Q1	FY2022 Q1				FY2022			
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)	
	<b>Trastuzumab deruxtecan</b> anti-cancer agent (HER2-directed antibody drug conjugate)	<b>16.0</b>	<b>37.4</b>	<b>(23.4%)</b>	<b>21.4</b>	<b>+134.3%</b>	<b>159.9</b>	<b>79.1</b>	<b>+97.8%</b>	
	Product sales *Incl. Gross profit share in AstraZeneca territory	13.0	31.3	(24.4%)	18.4	+141.7%	128.4	63.0	+96.4%	
	Enhertu (JPN)	2.2	2.4	(15.1%)	0.3	+11.5%	16.0	6.4	+67.4%	
	Enhertu (US)	9.6	20.0	(24.1%)	10.5	+109.0%	83.1	37.7	+83.0%	
	Enhertu (EU)	1.2	6.7	(29.0%)	5.5	+458.8%	23.0	14.0	+154.7%	
	Enhertu (ASCA: Asia, South and Central America)	-	2.2	(34.6%)	2.2	-	6.3	4.9	+355.8%	
	Upfront payment	2.5	2.5	(25.0%)	-	-	9.8	-	-	
	Regulatory milestone payment	0.6	3.4	(16.3%)	2.8	+504.1%	20.6	18.3	+824.4%	
	US HER2+ Breast Cancer 3L	0.2	0.2	(25.0%)	-	-	0.9	-	-	
	EU HER2+ Breast Cancer 3L	0.1	0.1	(25.0%)	-	-	0.5	-	-	
	US HER2+ Gastric Cancer 2L/3L	0.2	0.2	(25.0%)	-	-	0.8	-	-	
	US HER2+ Breast Cancer 2L	-	2.8	(81.8%)	2.8	-	3.4	3.4	-	
	EU HER2+ Breast Cancer 2L	-	-	-	-	-	2.6	2.6	-	
	US HER2-low Breast Cancer (post chemo)	-	-	-	-	-	6.9	6.9	-	
	EU HER2+ Gastric Cancer 2L	-	-	-	-	-	1.2	1.2	-	
	US HER2+ or HER2 Mutated NSCLC 2L	-	-	-	-	-	4.3	4.3	-	
	Quid related payment*	-	0.3	(25.0%)	0.3	-	1.1	-2.3	-66.7%	
	*Payment which shall be paid by AstraZeneca to Daiichi Sankyo if both parties do not enter into potential licensing opportunity (Granting Daiichi Sankyo rights to develop or commercialize AstraZeneca's proprietary products, programs or technologies)									
	<b>Datopotamab deruxtecan</b> anti-cancer agent (TROP2-directed antibody drug conjugate)	<b>1.5</b>	<b>1.5</b>	<b>(21.5%)</b>	<b>0.0</b>	<b>+2.7%</b>	<b>6.9</b>	<b>0.9</b>	<b>+14.1%</b>	
	Upfront payment	1.5	1.5	(21.5%)	0.0	+2.7%	6.9	0.9	+14.1%	

### 3. Revenue of Global Products (2)

JPY Bn		FY2021 Q1	FY2022 Q1				FY2022		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
<b>Edoxaban</b>	anticoagulant	<b>49.5</b>	<b>58.9</b>	<b>(24.8%)</b>	<b>9.4</b>	<b>+18.9%</b>	<b>237.7</b>	<b>32.1</b>	<b>+15.6%</b>
	Lixiana (JPN)	22.9	25.1	(24.1%)	2.2	+9.7%	104.3	11.8	+12.8%
	Savaysa (US)	0.5	0.6	(24.2%)	0.1	+15.0%	2.4	0.5	+26.4%
	Lixiana (EU)	23.4	28.6	(25.5%)	5.2	+22.3%	112.1	15.2	+15.7%
	Edoxaban (ASCA: Asia, South and Central America)	2.7	4.6	(24.3%)	1.8	+67.3%	18.8	4.5	+31.8%

#### 4. Revenue by Business Units and Products (1)

JPY Bn

		FY2021 Q1	FY2022 Q1				FY2022		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
<b>Japan Business Unit</b>		<b>129.1</b>	<b>109.0</b>	<b>(22.5%)</b>	<b>-20.1</b>	<b>-15.5%</b>	<b>483.8</b>	<b>-5.7</b>	<b>-1.2%</b>
Lixiana	anticoagulant	22.9	25.1	(24.1%)	2.2	+9.7%	104.3	11.8	+12.8%
Tarlige	pain treatment	7.1	8.9	(23.2%)	1.8	+25.8%	38.2	8.1	+26.8%
Pralia	treatment for osteoporosis/ inhibitor of the progression of bone erosion	9.2	9.9	(27.5%)	0.7	+8.2%	36.0	-1.9	-5.0%
Efient	antiplatelet agent	4.1	4.9	(20.6%)	0.7	+17.2%	23.5	6.8	+40.7%
Tenelia	type 2 diabetes mellitus treatment	6.4	5.6	(24.1%)	-0.8	-12.7%	23.0	-0.6	-2.6%
Vimpat	anti-epileptic agent	4.5	5.3	(24.2%)	0.8	+17.4%	21.9	3.6	+19.5%
Ranmark	treatment for bone complications caused by bone metastases from tumors	5.1	4.9	(23.5%)	-0.2	-3.7%	21.0	0.6	+2.9%
Canalia	type 2 diabetes mellitus treatment	4.3	4.1	(21.6%)	-0.3	-6.4%	18.8	2.0	+11.9%
Loxonin	anti-inflammatory analgesic	5.8	4.6	(26.3%)	-1.2	-20.3%	17.5	-4.7	-21.0%
Enhertu	anti-cancer agent (HER2-directed antibody drug conjugate)	2.2	2.4	(15.1%)	0.3	+11.5%	16.0	6.4	+67.4%
Emgality	prophylaxis of migraine attacks	0.9	1.4	(11.0%)	0.6	+64.5%	13.1	8.5	+182.8%
Daiichi Sankyo Espha products		20.0	21.0	-	1.0	+4.9%	not disclosed	-	-
Vaccines business		1.4	0.5	-	-0.9	-61.6%	not disclosed	-	-
<b>Daiichi Sankyo Healthcare Unit</b>		<b>15.4</b>	<b>15.3</b>	<b>(22.0%)</b>	<b>-0.1</b>	<b>-0.9%</b>	<b>69.4</b>	<b>4.7</b>	<b>+7.3%</b>

#### 4. Revenue by Business Units and Products (2)

JPY Bn	FY2021 Q1		FY2022 Q1				FY2022		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
<b>Oncology Business Unit</b>	<b>14.5</b>		<b>27.5</b>	<b>(25.0%)</b>	<b>13.1</b>	<b>+90.2%</b>	<b>110.0</b>	<b>40.4</b>	<b>+58.1%</b>
Enhertu	10.8		26.7	(25.2%)	15.9	+147.5%	106.1	51.7	+94.9%
Enhertu (US)	9.6		20.0	(24.1%)	10.5	+109.0%	83.1	37.7	+83.0%
Enhertu (EU)	1.2		6.7	(29.0%)	5.5	+458.8%	23.0	14.0	+154.7%
TURALIO	0.6		0.8	(20.4%)	0.2	+28.8%	3.9	1.1	+40.7%
<b>American Regent Unit</b>	<b>39.1</b>		<b>47.0</b>	<b>(26.7%)</b>	<b>7.9</b>	<b>+20.3%</b>	<b>175.8</b>	<b>26.3</b>	<b>+17.6%</b>
Injectafer	14.9		14.1	(22.4%)	-0.8	-5.1%	63.1	10.0	+18.8%
Venofer	7.9		12.4	(33.1%)	4.5	+56.3%	37.4	3.6	+10.8%
<b>EU Specialty Business Unit</b>	<b>32.7</b>		<b>37.1</b>	<b>(26.6%)</b>	<b>4.4</b>	<b>+13.5%</b>	<b>139.5</b>	<b>11.2</b>	<b>+8.7%</b>
Lixiana	23.4		28.6	(25.5%)	5.2	+22.3%	112.1	15.2	+15.7%
Nilemdo/Nustendi	0.7		1.3	(18.8%)	0.6	+83.2%	7.1	4.0	+127.0%
Olmesartan	5.6		5.4	(33.6%)	-0.2	-3.8%	16.1	-4.2	-20.8%
<b>ASCA Business Unit</b>	<b>26.5</b>		<b>31.9</b>	<b>(25.3%)</b>	<b>5.4</b>	<b>+20.5%</b>	<b>126.3</b>	<b>12.1</b>	<b>+10.6%</b>
Daiichi Sankyo China	11.8		13.3	(21.9%)	1.6	+13.2%	61.0	7.7	+14.4%
Daiichi Sankyo Korea	5.8		6.1	(26.7%)	0.3	+5.1%	23.0	-0.1	-0.5%
Daiichi Sankyo Brasil Farmacêutica	3.3		4.8	(27.7%)	1.5	+45.2%	17.2	3.6	+26.0%
Daiichi Sankyo Taiwan	2.3		3.1	(31.5%)	0.8	+35.3%	9.9	-0.1	-1.1%
Daiichi Sankyo Thailand	0.5		0.6	(28.1%)	0.1	+28.1%	2.3	0.1	+4.9%
Daiichi Sankyo Hong Kong	0.3		0.6	(14.3%)	0.4	+139.0%	4.4	2.7	+165.8%



#### 4. Revenue by Business Units and Products (3)

##### [Reference] Revenue in Local Currency

		FY2021 Q1	FY2022 Q1				FY2022		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
USD Mn									
<b>Oncology Business Unit</b>		<b>132</b>	<b>212</b>	<b>(25.1%)</b>	<b>80</b>	<b>+60.8%</b>	<b>846</b>	<b>227</b>	<b>+36.6%</b>
Enhertu	anti-cancer agent (HER2-directed antibody drug conjugate)	99	206	(25.3%)	108	+109.1%	816	332	+68.5%
Enhertu (US)		88	155	(24.2%)	67	+76.7%	639	235	+58.2%
Enhertu (EU)		11	52	(29.1%)	41	3.7	177	97	+120.2%
TURALIO	anti-cancer agent	6	6	(20.5%)	1	+8.9%	30	5	+21.6%
USD Mn									
<b>American Regent Unit</b>		<b>357</b>	<b>363</b>	<b>(26.8%)</b>	<b>6</b>	<b>+1.7%</b>	<b>1,352</b>	<b>22</b>	<b>+1.7%</b>
Injectafer	treatment for iron deficiency anemia	136	109	(22.4%)	-27	-19.8%	485	13	+2.7%
Venofer	treatment for iron deficiency anemia	72	96	(33.2%)	23	+32.1%	288	-13	-4.3%
EUR Mn									
<b>EU Specialty Business Unit</b>		<b>248</b>	<b>269</b>	<b>(27.0%)</b>	<b>21</b>	<b>+8.5%</b>	<b>996</b>	<b>14</b>	<b>+1.4%</b>
Lixiana	anticoagulant	177	207	(25.9%)	30	+16.9%	801	58	+7.9%
Nilemdo/Nustendi	cholesterol-lowering agent	6	10	(19.0%)	4	+75.0%	51	27	+111.7%
Olmesartan	antihypertensive agent	43	39	(34.1%)	-3	-8.1%	115	-41	-26.1%

## 5. Consolidated Statement of Financial Position

<Assets>

JPY Bn

	Mar. 2022	Jun. 2022	vs. Mar. 2022
<b>Assets</b>			
Current assets			
Cash and cash equivalents	662.5	658.1	-4.4
Trade and other receivables	266.7	291.0	24.4
Other financial assets	181.4	149.1	-32.2
Inventories	217.9	249.3	31.4
Other current assets	16.8	19.6	2.7
<b>Total current assets</b>	<b>1,345.3</b>	<b>1,367.1</b>	<b>21.9</b>
Non-current assets			
Property, plant and equipment	304.1	318.3	14.2
Goodwill	83.6	90.7	7.1
Intangible assets	163.9	171.3	7.4
Investments accounted for using the equity method	1.4	1.3	-0.1
Other financial assets	131.5	136.2	4.7
Deferred tax assets	138.2	139.1	0.9
Other non-current assets	53.5	70.5	17.0
<b>Total non-current assets</b>	<b>876.1</b>	<b>927.4</b>	<b>51.3</b>
<b>Total assets</b>	<b>2,221.4</b>	<b>2,294.5</b>	<b>73.1</b>
* Liquidity on hand	842.9	806.8	-36.2
Debt with interest	213.6	216.4	2.8
Net Cash	629.3	590.4	-38.9

Acquisition +14.8, Depreciation -8.7, Forex +8.5

Acquisition +5.1, Amortization -6.1, Forex +8.4

Investment securities +3.3

Contribution for equipment +17.1

## &lt;Liabilities and equity&gt;

JPY Bn

	Mar. 2022	Jun. 2022	vs. Mar. 2022
<b>Liabilities</b>			
Current liabilities			
Trade and other payables	324.8	330.3	5.5
Bonds and borrowings	20.4	20.4	0.0
Other financial liabilities	10.8	11.3	0.5
Income taxes payable	6.9	6.8	-0.1
Provisions	6.8	6.9	0.1
Other current liabilities	25.6	31.1	5.5
<b>Total current liabilities</b>	<b>395.3</b>	<b>406.8</b>	<b>11.5</b>
Non-current liabilities			
Bonds and borrowings	143.1	143.0	-0.1
Other financial liabilities	42.6	44.9	2.3
Post employment benefit liabilities	2.6	2.9	0.3
Provisions	18.3	18.3	0.0
Deferred tax liabilities	12.4	14.0	1.5
Other non-current liabilities	256.2	264.4	8.2
<b>Total non-current liabilities</b>	<b>475.3</b>	<b>487.5</b>	<b>12.2</b>
<b>Total liabilities</b>	<b>870.5</b>	<b>894.3</b>	<b>23.8</b>
<b>Equity</b>			
Equity attributable to owners of the Company			
Share capital	50.0	50.0	-
Treasury shares	-37.5	-37.4	0.1
Other components of equity	168.1	222.8	54.6
Retained earnings	1,170.2	1,164.9	-5.3
Total equity attributable to owners of the Company	1,350.9	1,400.3	49.4
<b>Total equity</b>	<b>1,350.9</b>	<b>1,400.3</b>	<b>49.4</b>
<b>Total liabilities and equity</b>	<b>2,221.4</b>	<b>2,294.5</b>	<b>73.1</b>

Deferred revenue for datopotamab deruxtecan -1.5  
(Strategic collaboration upfront payment -1.5)  
Deferred revenue for trastuzumab deruxtecan +6.1  
(Strategic collaboration upfront payment -2.5, Regulatory milestone payment +8.6)

Currency translation difference +53.7,  
Valuation difference on financial assets +1.0

Profit for the period +18.9, Payment of dividends -25.9

## 6. Consolidated Statement of Cash Flows

JPY Bn

	FY2021Q1	FY2022Q1	YoY
Cash flows from operating activities			
Profit before tax	47.1	29.4	-17.6
Depreciation and amortization	14.7	14.9	0.2
(Increase) decrease in receivables and payables	-59.0	-21.3	37.7
Others, net	-25.1	-34.2	-9.1
Income taxes paid	-7.8	-9.6	-1.8
<b>Net cash flows from operating activities</b>	<b>-30.1</b>	<b>-20.8</b>	<b>9.3</b>
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	52.0	48.2	-3.8
(Acquisition of) proceeds from sales of fixed assets	-19.8	-20.0	-0.2
Net (increase) decrease in investment securities	-2.1	-1.8	0.3
Others, net	-0.1	-0.1	-0.0
<b>Net cash flows from investing activities</b>	<b>30.0</b>	<b>26.3</b>	<b>-3.7</b>
Cash flows from financing activities			
Net (increase) decrease in borrowings	-0.1	-0.1	-0.0
Purchase of treasury shares	-0.0	-0.0	-0.0
Dividends paid	-25.9	-25.9	-0.0
Others, net	-3.3	-3.6	-0.4
<b>Net cash flows from financing activities</b>	<b>-29.3</b>	<b>-29.7</b>	<b>-0.4</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>-29.4</b>	<b>-24.1</b>	<b>5.3</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>380.5</b>	<b>662.5</b>	<b>281.9</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>	<b>1.1</b>	<b>19.7</b>	<b>18.6</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>352.3</b>	<b>658.1</b>	<b>305.8</b>
* <b>Free cash flows (Cash flows from operating activities and investing activities)</b>	<b>-0.1</b>	<b>5.5</b>	<b>5.6</b>

## 7. Number of Employees

	Jun. 2021	Mar. 2022	Jun. 2022
	Results	Results	Results
Consolidated	16,214	16,458	16,739
Japan	9,139	9,135	9,265
North America	2,659	2,706	2,743
Europe	2,212	2,279	2,337
Others	2,204	2,338	2,394

## 8. Capital Expenditure, Depreciation and Amortization

		Jun. 2021	Mar. 2022	Jun. 2022	FY2022
	JPY Bn	Results	Results	Results	Forecast
Capital expenditure		15.4	56.2	13.7	52.0
Depreciation and amortization		14.7	58.2	14.9	58.0
Property, plant and equipment		8.1	33.2	8.7	-
Intangible assets		6.6	25.1	6.2	-

## 9. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
<b>Japan Business Unit</b>						
Lixiana	edoxaban	anticoagulant	2011	Daiichi Sankyo		
Tarlige	mirogabalin	pain treatment	2019	Daiichi Sankyo		
Pralia	denosumab	treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	2013	Amgen		
Efient	prasugrel	antiplatelet agent	2014	Daiichi Sankyo Ube Industries		
Tenelia	teneligliptin	type 2 diabetes mellitus treatment	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Vimpat	lacosamide	anti-epileptic agent	2016	UCB	UCB	Co-promotion (DS: Sales)
Ranmark	denosumab	treatment for bone complications caused by bone metastases from tumors	2012	Amgen		
Canalia	teneligliptin / canagliflozin	type 2 diabetes mellitus treatment	2017	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice	loxoprofen	anti-inflammatory analgesic	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Enhertu	trastuzumab deruxtecan	anti-cancer agent (HER2-directed antibody drug conjugate)	2020	Daiichi Sankyo		
Emgality	galcanezumab-gnlm	Prophylaxis of migraine attacks	2021	Eli Lilly Japan	Eli Lilly Japan	Co-promotion (DS: Sales)
<b>Oncology Business Unit</b>						
Enhertu	trastuzumab deruxtecan	anti-cancer agent (HER2-directed antibody drug conjugate)	2020	Daiichi Sankyo	AstraZeneca	Co-promotion (DS: Sales)
Turalio	pexidartinib	anti-cancer agent	2019	Daiichi Sankyo		
<b>American Regent Unit</b>						
Injectafer	ferric carboxymaltose injection	treatment for iron deficiency anemia	2013	Vifor Pharma	Daiichi Sankyo, Inc.	Promotion (Daiichi Sankyo, Inc.)
Venofer	iron sucrose injection	treatment for iron deficiency anemia	2000	Vifor Pharma	Fresenius	Co-marketing
<b>EU Specialty Business Unit</b>						
Lixiana	edoxaban	anticoagulant	2015	Daiichi Sankyo	Merck (MSD)	Co-marketing
Nilemdo/Nustendi	bempedoic acid, bempedoic acid / ezetimibe	cholesterol-lowering agent	2020	Daiichi Sankyo	Esperion	
Olmesartan						
Olmetec	olmesartan		2002			
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive agent	2005	Daiichi Sankyo	Menarini Pfizer	Co-marketing
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			

<10. Quarterly Data>

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2021	FY2021	FY2021	FY2021	FY2021		FY2022	FY2022	FY2022	FY2022	FY2022			
	Q1	Q2	Q3	Q4	to revenue	Results	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)
	Results	Results	Results	Results			Results	Results	Results	Results				
<b>Revenue</b>	<b>264.1</b>	<b>265.9</b>	<b>281.0</b>	<b>233.9</b>	<b>100.0%</b>	<b>1,044.9</b>	<b>280.3</b>	-	-	-	<b>100.0%</b>	<b>280.3</b>	<b>16.2</b>	<b>+6.2%</b>
Cost of sales	85.2	87.4	90.6	84.8	33.3%	348.0	74.7	-	-	-	26.6%	74.7	-10.5	-12.3%
Gross Profit	178.9	178.5	190.4	149.1	66.7%	696.9	205.6	-	-	-	73.4%	205.6	26.7	+14.9%
SG&A expenses	81.2	84.5	90.0	96.4	33.7%	352.1	96.3	-	-	-	34.4%	96.3	15.1	+18.6%
R&D expenses	54.0	55.0	60.1	85.0	24.3%	254.1	74.9	-	-	-	26.7%	74.9	20.9	+38.7%
<b>Core Operating Profit</b>	<b>43.7</b>	<b>39.0</b>	<b>40.3</b>	<b>-32.4</b>	<b>8.7%</b>	<b>90.6</b>	<b>34.4</b>	-	-	-	<b>12.3%</b>	<b>34.4</b>	<b>-9.3</b>	<b>-21.3%</b>
Temporary income	2.1	0.0	0.0	1.8		3.9	0.0	-	-	-		0.0	-2.1	
Temporary expenses	0.0	0.1	1.3	20.1		21.5	-	-	-	-		-	-0.0	
<b>Operating Profit</b>	<b>45.8</b>	<b>39.0</b>	<b>39.0</b>	<b>-50.7</b>	<b>7.0%</b>	<b>73.0</b>	<b>34.4</b>	-	-	-	<b>12.3%</b>	<b>34.4</b>	<b>-11.4</b>	<b>-24.9%</b>
Financial income/expenses	1.3	-0.1	0.9	-1.7		0.4	-4.9	-	-	-		-4.9	-6.2	
Share of profit or loss of investments accounted for using the equity method	-0.0	0.0	0.0	0.1		0.1	-0.0	-	-	-		-0.0	-0.0	
<b>Profit before tax</b>	<b>47.1</b>	<b>38.9</b>	<b>39.9</b>	<b>-52.4</b>	<b>7.0%</b>	<b>73.5</b>	<b>29.4</b>	-	-	-	<b>10.5%</b>	<b>29.4</b>	<b>-17.6</b>	<b>-37.5%</b>
Income taxes	11.8	11.6	8.1	-25.0		6.5	10.6	-	-	-		10.6	-1.3	
<b>Profit for the year</b>	<b>35.2</b>	<b>27.2</b>	<b>31.9</b>	<b>-27.3</b>	<b>6.4%</b>	<b>67.0</b>	<b>18.9</b>	-	-	-	<b>6.7%</b>	<b>18.9</b>	<b>-16.4</b>	<b>-46.5%</b>
<b>Profit attributable to owners of the Company</b>	<b>35.2</b>	<b>27.2</b>	<b>31.9</b>	<b>-27.3</b>	<b>6.4%</b>	<b>67.0</b>	<b>18.9</b>	-	-	-	<b>6.7%</b>	<b>18.9</b>	<b>-16.4</b>	<b>-46.5%</b>
Tax rate	25.2%	29.9%	20.2%	-		8.9%	35.9%					35.9%		
Overseas sales ratio	44.7%	45.1%	45.7%	51.3%		46.6%	55.4%					55.4%		
Currency Rate (YTD Average)														
USD/JPY	109.49	110.11	113.71	116.21		112.38	129.57					129.57		
EUR/JPY	131.95	129.83	130.07	130.40		130.56	138.10					138.10		

<10. Quarterly Data>

**2. Revenue of Global Products**

	FY2021 Q1	FY2021 Q2	FY2021 Q3	FY2021 Q4	FY2021	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2022 Q4	FY2022
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
<b>Trastuzumab deruxtecan</b>	<b>16.0</b>	<b>16.8</b>	<b>22.9</b>	<b>25.1</b>	<b>80.8</b>	<b>37.4</b>	-	-	-	<b>37.4</b>
Product sales	13.0	13.8	16.8	21.9	65.4	31.3	-	-	-	31.3
Enhertu(JPN)	2.2	2.2	2.6	2.6	9.6	2.4	-	-	-	2.4
Enhertu (US)	9.6	10.1	11.9	13.8	45.4	20.0	-	-	-	20.0
Enhertu (EU)	1.2	1.4	2.3	4.1	9.0	6.7	-	-	-	6.7
Enhertu (ASCA: Asia, South and Central America)	-	-	-	1.4	1.4	2.2	-	-	-	2.2
Upfront payment	2.5	2.5	2.5	2.5	9.8	2.5	-	-	-	2.5
Regulatory milestone payment	0.6	0.6	0.6	0.6	2.2	3.4	-	-	-	3.4
US HER2+ Breast Cancer 3L	0.2	0.2	0.2	0.2	0.9	0.2	-	-	-	0.2
EU HER2+ Breast Cancer 3L	0.1	0.1	0.1	0.1	0.5	0.1	-	-	-	0.1
US HER2+ Gastric Cancer 2L/3L	0.2	0.2	0.2	0.2	0.8	0.2	-	-	-	0.2
US HER2+ Breast Cancer 2L	-	-	-	-	-	2.8	-	-	-	2.8
EU HER2+ Breast Cancer 2L	-	-	-	-	-	-	-	-	-	-
US HER2-low Breast Cancer (post chemo)	-	-	-	-	-	-	-	-	-	-
EU HER2+ Gastric Cancer 2L	-	-	-	-	-	-	-	-	-	-
US HER2+ or HER2 Mutant NSCLC 2L	-	-	-	-	-	-	-	-	-	-
QUID related payment	-	-	3.1	0.3	3.4	0.3	-	-	-	0.3
<b>Datopotamab deruxtecan</b>	<b>1.5</b>	<b>1.6</b>	<b>1.5</b>	<b>1.5</b>	<b>6.1</b>	<b>1.5</b>	-	-	-	<b>1.5</b>
Upfront payment	1.5	1.6	1.5	1.5	6.1	1.5	-	-	-	1.5
<b>Edoxaban</b>	<b>49.5</b>	<b>49.7</b>	<b>57.0</b>	<b>49.4</b>	<b>205.6</b>	<b>58.9</b>	-	-	-	<b>58.9</b>
Lixiana (JPN)	22.9	21.9	25.6	22.0	92.5	25.1	-	-	-	25.1
Savaysa (US)	0.5	0.5	0.4	0.5	1.9	0.6	-	-	-	0.6
Lixiana (EU)	23.4	23.7	27.2	22.6	96.9	28.6	-	-	-	28.6
Edoxaban (ASCA: Asia, South and Central America)	2.7	3.6	3.8	4.2	14.3	4.6	-	-	-	4.6



<b>3. Revenue by Business Units and Products (1)</b>	<b>FY2021 Q1</b>	<b>FY2021 Q2</b>	<b>FY2021 Q3</b>	<b>FY2021 Q4</b>	<b>FY2021</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
<b>Japan Business Unit</b>	<b>129.1</b>	<b>126.5</b>	<b>138.1</b>	<b>95.8</b>	<b>489.5</b>	<b>109.0</b>	-	-	-	<b>109.0</b>
Lixiana	22.9	21.9	25.6	22.0	92.5	25.1	-	-	-	25.1
Tarlige	7.1	7.1	8.7	7.3	30.1	8.9	-	-	-	8.9
Pralia	9.2	9.3	10.3	9.2	37.9	9.9	-	-	-	9.9
Efient	4.1	3.9	4.7	4.0	16.7	4.9	-	-	-	4.9
Tenelia	6.4	5.7	6.5	5.1	23.7	5.6	-	-	-	5.6
Vimpat	4.5	4.4	5.1	4.3	18.3	5.3	-	-	-	5.3
Ranmark	5.1	5.0	5.5	4.8	20.4	4.9	-	-	-	4.9
Canalia	4.3	4.0	4.7	3.8	16.8	4.1	-	-	-	4.1
Loxonin	5.8	5.5	6.3	4.6	22.2	4.6	-	-	-	4.6
Enhertu	2.2	2.2	2.6	2.6	9.6	2.4	-	-	-	2.4
Emgality	0.9	1.2	1.3	1.2	4.6	1.4	-	-	-	1.4
Daiichi Sankyo Espha products	20.0	19.8	24.2	18.8	82.8	21.0	-	-	-	21.0
Vaccines business	1.4	4.0	12.3	-2.9	14.8	0.5	-	-	-	0.5
<b>Daiichi Sankyo Healthcare Unit</b>	<b>15.4</b>	<b>18.4</b>	<b>15.9</b>	<b>15.0</b>	<b>64.7</b>	<b>15.3</b>	-	-	-	<b>15.3</b>

<b>3. Revenue by Business Units and Products (2)</b>	<b>FY2021 Q1</b>	<b>FY2021 Q2</b>	<b>FY2021 Q3</b>	<b>FY2021 Q4</b>	<b>FY2021</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>
JPY Bn	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
<b>Oncology Business Unit</b>	<b>14.5</b>	<b>16.6</b>	<b>18.1</b>	<b>20.4</b>	<b>69.6</b>	<b>27.5</b>	-	-	-	<b>27.5</b>
Enhertu	10.8	11.6	14.2	17.9	54.4	26.7	-	-	-	26.7
Enhertu (US)	9.6	10.1	11.9	13.8	45.4	20.0	-	-	-	20.0
Enhertu (EU)	1.2	1.4	2.3	4.1	9.0	6.7	-	-	-	6.7
Turalio	0.6	0.7	0.7	0.8	2.8	0.8	-	-	-	0.8
<b>American Regent Unit</b>	<b>39.1</b>	<b>37.9</b>	<b>38.7</b>	<b>33.8</b>	<b>149.5</b>	<b>47.0</b>	-	-	-	<b>47.0</b>
Injectafer	14.9	14.1	13.4	10.7	53.1	14.1	-	-	-	14.1
Venofer	7.9	8.6	8.8	8.5	33.8	12.4	-	-	-	12.4
<b>EU Specialty Business Unit</b>	<b>32.7</b>	<b>30.9</b>	<b>34.3</b>	<b>30.3</b>	<b>128.2</b>	<b>37.1</b>	-	-	-	<b>37.1</b>
Lixiana	23.4	23.7	27.2	22.6	96.9	28.6	-	-	-	28.6
Nilemdo/Nustendi	0.7	0.9	0.6	0.9	3.1	1.3	-	-	-	1.3
Olmesartan	5.6	4.7	4.6	5.4	20.3	5.4	-	-	-	5.4
<b>ASCA Business Unit</b>	<b>26.5</b>	<b>28.6</b>	<b>27.9</b>	<b>31.2</b>	<b>114.1</b>	<b>31.9</b>	-	-	-	<b>31.9</b>
Daiichi Sankyo China	11.8	13.7	13.0	14.8	53.3	13.3	-	-	-	13.3
Daiichi Sankyo Korea	5.8	6.1	5.9	5.3	23.2	6.1	-	-	-	6.1
Daiichi Sankyo Brasil Farmacêutica	3.3	3.2	3.6	3.6	13.7	4.8	-	-	-	4.8
Daiichi Sankyo Taiwan	2.3	2.3	2.2	3.3	10.0	3.1	-	-	-	3.1
Daiichi Sankyo Thailand	0.5	0.5	0.5	0.6	2.2	0.6	-	-	-	0.6
Daiichi Sankyo Hong Kong	0.3	0.1	0.4	0.9	1.7	0.6	-	-	-	0.6

<b>3. Revenue by Business Units and Products (3)</b>	<b>FY2021 Q1</b>	<b>FY2021 Q2</b>	<b>FY2021 Q3</b>	<b>FY2021 Q4</b>	<b>FY2021</b>	<b>FY2022 Q1</b>	<b>FY2022 Q2</b>	<b>FY2022 Q3</b>	<b>FY2022 Q4</b>	<b>FY2022</b>
<b>[Reference] Revenue in Local Currency</b>	Results	Results	Results	Results	Results	Results	Results	Results	Results	Results
USD Mn										
<b>Oncology Business Unit</b>	<b>132</b>	<b>150</b>	<b>160</b>	<b>177</b>	<b>619</b>	<b>212</b>	-	-	-	<b>212</b>
Enhertu	99	105	125	155	484	206	-	-	-	206
Enhertu (US)	88	92	105	119	404	155	-	-	-	155
Enhertu (EU)	11	13	20	36	80	52	-	-	-	52
Turalio	6	6	6	7	25	6	-	-	-	6
USD Mn										
<b>American Regent Unit</b>	<b>357</b>	<b>344</b>	<b>340</b>	<b>289</b>	<b>1,330</b>	<b>363</b>	-	-	-	<b>363</b>
Injectafer	136	128	118	91	472	109	-	-	-	109
Venofer	72	78	77	73	300	96	-	-	-	96
EUR Mn										
<b>EU Specialty Business Unit</b>	<b>248</b>	<b>238</b>	<b>263</b>	<b>232</b>	<b>982</b>	<b>269</b>	-	-	-	<b>269</b>
Lixiana	177	182	209	174	742	207	-	-	-	207
Nilemdo/Nustendi	6	7	5	7	24	10	-	-	-	10
Olmesartan	43	36	36	41	155	39	-	-	-	39

## <11. Historical Data>

### 1. Revenue of Global Products

	FY2017	FY2018	FY2019	FY2020	FY2021
JPY Bn	Results	Results	Results	Results	Results
<b>Trastuzumab deruxtecan</b>	-	0.1	14.0	43.5	80.8
Product sales	-	-	3.2	30.1	65.4
Enhertu (JPN)	-	-	-	4.4	9.6
Enhertu (US)	-	-	3.2	25.7	45.4
Enhertu (EU)	-	-	-	0.0	9.0
Enhertu (ASCA: Asia, South and Central America)	-	-	-	-	1.4
Upfront payment	-	0.1	9.8	9.8	9.8
Regulatory milestone payment	-	-	0.9	3.5	2.2
US HER2+ Breast Cancer 3L	-	-	0.9	0.9	0.9
EU HER2+ Breast Cancer 3L	-	-	-	1.0	0.5
US HER2+ Gastric Cancer 2L/3L	-	-	-	1.6	0.8
US HER2+ Breast Cancer 2L	-	-	-	-	-
EU HER2+ Breast Cancer 2L	-	-	-	-	-
US HER2-low Breast Cancer (post-chemo)	-	-	-	-	-
EU HER2+ Gastric Cancer 2L	-	-	-	-	-
US HER2+ or HER2 Mutant NSCLC 2L	-	-	-	-	-
<b>Datopotamab deruxtecan</b>	-	-	-	3.9	6.1
Upfront payment	-	-	-	3.9	6.1
<b>Edoxaban</b>	77.1	117.7	154.0	165.9	205.6
Lixiana (JPN)	45.3	64.9	83.0	77.4	92.5
Savaysa (US)	2.2	2.3	2.6	3.0	1.9
Lixiana (EU)	27.0	45.8	61.7	76.7	96.9
Other subsidiaries	2.6	4.7	6.8	8.9	14.3

**2. Revenue by Business Units and Products (1)**

	FY2017	FY2018	FY2019	FY2020	FY2021
JPY Bn	Results	Results	Results	Results	Results
<b>Japan Business Unit</b>	<b>540.0</b>	<b>523.3</b>	<b>533.5</b>	<b>489.1</b>	<b>489.5</b>
Lixiana	45.3	64.9	83.0	77.4	92.5
Tarlige	-	-	8.0	20.6	30.1
Pralia	23.2	27.4	30.9	34.6	37.9
Efient	12.8	13.9	14.0	14.1	16.7
Tenelia	26.3	25.3	24.7	24.2	23.7
Vimpat	2.6	6.6	11.2	14.5	18.3
Ranmark	15.4	16.4	17.9	19.3	20.4
Canalia	2.7	9.2	12.8	15.4	16.8
Loxonin	36.5	30.5	28.3	24.2	22.2
Enhertu	-	-	-	4.4	9.6
Emgality	-	-	-	-	4.6
Inavir	25.3	18.2	19.3	3.6	1.3
Daiichi Sankyo Espha products	46.7	55.5	60.5	71.4	82.8
Vaccines business	41.9	41.5	35.6	18.5	14.8
<b>Daiichi Sankyo Healthcare Unit</b>	<b>72.9</b>	<b>66.4</b>	<b>68.5</b>	<b>67.2</b>	<b>64.7</b>

## 2. Revenue by Business Units and Products (2)

	FY2017	FY2018	FY2019	FY2020	FY2021
JPY Bn	Results	Results	Results	Results	Results
<b>Oncology Business Unit</b>	<b>74.8</b>	<b>36.3</b>	<b>32.1</b>	<b>47.4</b>	<b>69.6</b>
Enhertu	-	-	3.2	25.7	54.4
Enhertu (US)	-	-	3.2	25.7	45.4
Enhertu (EU)	-	-	-	0.0	9.0
Turalio	-	-	-	1.8	2.8
Olmesartan	21.3	10.7	9.8	8.6	5.0
Welchol	33.9	13.4	9.1	5.0	3.2
Effient	10.7	2.4	0.5	0.3	0.2
Savaysa	2.2	2.3	2.6	3.0	1.9
<b>American Regent Unit</b>	<b>105.4</b>	<b>117.8</b>	<b>130.8</b>	<b>121.7</b>	<b>149.5</b>
Injectafer	34.3	44.2	51.8	44.1	53.1
Venofer	31.0	28.9	31.0	28.8	33.8
<b>EU Specialty Business Unit</b>	<b>79.4</b>	<b>88.6</b>	<b>95.5</b>	<b>111.7</b>	<b>128.2</b>
Lixiana	27.0	45.8	61.7	76.7	96.9
Nilemdo/Nustendi	-	-	-	0.6	3.1
Olmesartan	33.5	27.4	24.6	21.5	20.3
Efient	8.0	5.7	2.5	1.6	1.5
<b>ASCA Business Unit</b>	<b>80.4</b>	<b>87.7</b>	<b>98.3</b>	<b>99.7</b>	<b>114.1</b>
Daiichi Sankyo China	35.3	38.5	46.0	45.6	53.3
Daiichi Sankyo Korea	11.8	15.7	17.2	19.6	23.2
Daiichi Sankyo Brasil Farmacêutica	10.1	10.0	11.5	10.5	13.7
Daiichi Sankyo Taiwan	6.6	7.1	7.6	8.3	10.0
Daiichi Sankyo Thailand	2.9	3.3	3.3	2.3	2.2
Daiichi Sankyo Hong Kong	-	-	-	0.7	1.7

**2. Revenue by Business Units and Products (3)****[Reference] Revenue in Local Currency**

	FY2017	FY2018	FY2019	FY2020	FY2021
	Results	Results	Results	Results	Results
USD Mn					
<b>Oncology Business Unit</b>	<b>674</b>	<b>327</b>	<b>295</b>	<b>447</b>	<b>619</b>
Enhertu	-	-	30	243	484
Enhertu (US)	-	-	30	243	404
Enhertu (EU)	-	-	-	0	80
Turalio	-	-	-	17	25
Olmesartan	192	97	91	81	45
Welchol	306	121	84	47	28
Effient	96	22	4	3	2
Savaysa	20	21	24	28	17
USD Mn					
<b>American Regent Unit</b>	<b>951</b>	<b>1,062</b>	<b>1,204</b>	<b>1,148</b>	<b>1,330</b>
Injectafer	310	399	477	416	472
Venofer	279	261	285	272	300
EUR Mn					
<b>EU Specialty Business Unit</b>	<b>613</b>	<b>690</b>	<b>789</b>	<b>903</b>	<b>982</b>
Lixiana	208	357	509	620	742
Nilemdo/Nustendi	-	-	-	5	24
Olmesartan	258	213	203	174	155
Efient	62	44	21	13	12

◆ Explanation of Description

**Generic name/Project Code Number (mechanism of action)**

Detail on its mechanism

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
<ul style="list-style-type: none"> <li>Phase of the study</li> <li>Study Name (if applicable)</li> <li>CTG registration number</li> <li>JapicCTI/jRCT registration number</li> <li>Partner, if applicable</li> </ul>	Patients and target indications for the study	Target sample size	Study design schematic (randomize or not, blinding or not, control group or not)	<ul style="list-style-type: none"> <li>Primary and secondary endpoints are listed</li> <li>Safety measures are summarized as "safety"</li> <li>Pharmacokinetic indices are summarized as "PK"</li> </ul>	Region under study (not consistent with region under development)	<ul style="list-style-type: none"> <li>Announcements as these trials open</li> <li>Scheduled time to achieve TLR (LPD if achieved)</li> <li>Schedule timing of submission for late-phase projects</li> <li>Application status, status of obtaining various review preference systems, etc.</li> </ul>

◆ List of Abbreviations

ADA: ant-drug antibody; ADC: antibody drug conjugate; AML: acute myeloid leukemia, BMFI: brain metastases-free interval, CR: complete remission, CRL: complete response letter, DCR: disease control rate, DFS: disease-free survival, DOR: duration of response, DRFI: distant recurrence-free interval, EFS: event-free survival, FPD: first patient dosed, FSD: first subject dosed, IDFS: invasive disease-free survival, LPD: last patient dosed, NSCLC: non small cell lung cancer, ORR: overall response rate/objective response rate, OS: overall survival, pCR: pathological complete response, PFS: progression-free survival, PK: pharmacokinetics, SCLC: small cell lung cancer, TLR: top line results, TNBC: triple negative breast cancer, TTR: time to response



### ◆ 3 ADCs

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting HER2, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Brand name: ENHERTU (JP/US/EU)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 (pivotal) DESTINY-Breast01  NCT03248492 JapicCTI-173693  AstraZeneca	HER2 positive breast cancer, 3L	253	Randomized, open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, DOR, PFS, OS, etc.	JP/US/EU /Asia	FPD: Oct 2017 TLR: May 2019  Jan 2020: Launch (US) May 2020: Launch (JP) Feb 2021: Launch (EU)
Phase 3 DESTINY-Breast02  NCT03523585 JapicCTI-184017  AstraZeneca	HER2 positive breast cancer, 3L	600	Randomized, open label, active control •DS-8201 •Physician's choice (trastuzumab + capecitabine or lapatinib + capecitabine)	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS, etc.	JP/US/EU /Asia	FPD: Sep 2018 TLR: FY2022 Q2
Phase 3 DESTINY-Breast03  NCT03529110 JapicCTI-183976  AstraZeneca	HER2 positive breast cancer, 2L	500	Randomized, open label, active control •DS-8201 •T-DM1	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, PFS, etc.	JP/US/EU /Asia	FPD: Aug 2018 TLR: Aug 2021  Dec 2021: Filing accepted (JP) Mar 2022: Filing accepted (CN) May 2022: Approval (US) Jul 2022: Approval (EU)  Aug 2021: Real Time Oncology Review Designation (US) Sep 2021: Breakthrough Therapy Designation (US)

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 DESTINY-Breast04  NCT03734029 JapicCTI-184223  AstraZeneca	HER2 low breast cancer, post chemotherapy	540	Randomized, open label, active control •DS-8201 •Physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel)	Primary endpoint: PFS Secondary endpoint: OS, ORR, DOR, etc.	JP/US/EU /Asia	FPD: Dec 2018 TLR: Feb 2022  Jun 2022: Filing accepted (JP/EU) Jul 2022: Filing accepted (US)  Feb 2022: Real Time Oncology Review Designation (US) Apr 2022: Breakthrough Therapy Designation (US)
Phase 3 DESTINY-Breast05  NCT04622319 jRCT2061200033  AstraZeneca	HER2 positive, with residual invasive breast cancer following neoadjuvant therapy	1,600	Randomized, open label, active control •DS-8201 •T-DM1	Primary endpoint: IDFS Secondary endpoint: DFS, OS, DRFI, BMFI, safety, PK, etc.	JP/US/EU /Asia	FPD: Dec 2020
Phase3 DESTINY-Breast06  NCT04494425 jRCT2061200028  AstraZeneca	HER2 low/HR positive breast cancer, chemotherapy naïve	850	Randomized, open label, active control •DS-8201 •Physician's choice (capecitabine, paclitaxel or nab-paclitaxel)	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, safety, etc.	JP/US/EU /Asia	FPD: Aug 2020
Phase1b/2 DESTINY-Breast07  NCT04538742  AstraZeneca	HER2 positive breast cancer Part 1: 2L or later Part 2: 1L	450	Open label, two-part (dose escalation, dose expansion) •DS-8201 + durvalumab •DS-8201 + pertuzumab •DS-8201 + paclitaxel •DS-8201 + durvalumab + paclitaxel •DS-8201 + tucatinib •DS-8201	Primary endpoint: Safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: Jan 2021

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase1b DESTINY-Breast08  NCT04556773  AstraZeneca	HER2 low breast cancer chemotherapy naïve, post chemotherapy	185	Open label, two-part (dose escalation, dose expansion) •DS-8201 + capecitabine •DS-8201 + durvalumab + paclitaxel •DS-8201 + capivasertib (AZD5363) •DS-8201 + anastrozole •DS-8201 + fulvestrant	Primary endpoint: Safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: Jan 2021
Phase3 DESTINY-Breast09  NCT04784715 jRCT2031210130  AstraZeneca	HER2 positive breast cancer, 1L	1,134	Randomized, open label, active control •DS-8201 •DS-8201 + pertuzumab •Taxane + trastuzumab + pertuzumab	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, PK, safety, etc.	JP/US/EU /Asia	FPD: Jun 2021
Phase3 DESTINY-Breast11  NCT05113251 jRCT2041210097  AstraZeneca	HER2 positive breast cancer, neoadjuvant	624	Randomized, open label, active control •DS-8201 •DS-8201, followed by paclitaxel + trastuzumab + pertuzumab •doxorubicin + cyclophosphamide, followed by paclitaxel + trastuzumab + pertuzumab	Primary endpoint: pCR Secondary endpoint: EFS, IDFS, OS	JP/US/EU /Asia	FPD: Nov 2021
Phase 1b/2 BEGONIA  NCT03742102  AstraZeneca	TNBC	200	Non-randomized, open label, combination with durvalumab •DS-8201 + durvalumab  * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: Safety Secondary endpoint: ORR, PFS, DOR, OS, PK, etc.	US/EU /Asia	FPD: May 2020
Phase 2 (pivotal) DESTINY-Gastric01  NCT03329690 JapicCTI-173727  AstraZeneca	HER2 expressing, gastric or gastroesophageal junction adenocarcinoma, 3L	220	Randomized, open label, active control •DS-8201 •Physician's choice (irinotecan or paclitaxel)	Primary endpoint: ORR Secondary endpoint: PFS, OS, DOR, DCR, TTF, ORR, PK	JP/Asia	FPD: Nov 2017 TLR: Jan 2020 Sep 2020: Approval (JP) Jan 2021: Approval (US)  Mar 2018: SAKIGAKE Designation (JP) May 2020: Breakthrough Therapy Designation (US) May 2020: Orphan Drug Designation (US)

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-Gastric02  NCT04014075 AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma 2L	72	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: PFS, ORR, OS, DOR	US/EU	FPD: Dec 2019 TLR: Jun 2021 Nov 2021: Filing accepted (EU)
Phase 1b/2 DESTINY-Gastric03  NCT04379596 jRCT2031200203  AstraZeneca	HER2 positive gastric/gastroesophageal junction and esophageal adenocarcinoma Part1: 2L Part 2: 1L	255	Randomized, open label Part 1 •DS-8201 + fluorouracil •DS-8201 + capecitabine •DS-8201 + durvalumab •DS-8201 + oxaliplatin + fluorouracil •DS-8201 + capecitabine + oxaliplatin •DS-8201 + durvalumab + fluorouracil •DS-8201 + capecitabine + durvalumab  Part 2 •DS-8201 •DS-8201 + oxaliplatin + fluorouracil or capecitabine •DS-8201 + pembrolizumab + fluorouracil or capecitabine •DS-8201 + pembrolizumab •Trastuzumab + fluorouracil or capecitabine + cisplatin or oxaliplatin	Primary endpoint: Part 1: Safety, Part 2: ORR Secondary endpoint: ORR, safety, DOR, DCR, PFS, OS, PK	JP/US/EU /Asia	FPD: Jun 2020
Phase 3 DESTINY-Gastric04  NCT04704934 jRCT2031200369  AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 2L	490	Randomized, open label •DS-8201 •Ramucirumab + paclitaxel	Primary endpoint: OS Secondary endpoint: PFS, ORR, DOR, DCR, safety, PK, ADA, etc.	JP/EU /Asia	FPD: Jun 2021

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-Gastric06  NCT04989816  AstraZeneca	HER2 positive gastric or gastroesophageal junction adenocarcinoma, 3L	100	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, PFS, DCR, DOR, OS, Tumor size change, PK, ADA	China	FPD: Sep 2021
Phase 2 DESTINY-Lung01  NCT03505710 JapicCTI-183916  AstraZeneca	HER2 overexpressing or mutated NSCLC, 2L or later	170	Non-randomized, open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, DOR, PFS, OS	JP/US/EU	FPD: May 2018 TLR: Jun 2021  Apr 2022: Filing accepted (US)  May 2020: Breakthrough Therapy Designation (US)
Phase 2 DESTINY-Lung02  NCT04644237 jRCT2061200038  AstraZeneca	HER2 mutated NSCLC, 2L or later	150	Randomized, double blind •DS-8201: 6.4mg/kg •DS-8201: 5.4mg/kg	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, PFS, OS, safety	JP/US/EU /Asia	FPD: Mar 2021
Phase 1b DESTINY-Lung03  NCT04686305  AstraZeneca	HER2 positive NSCLC, 1L	120	Non-randomized, three-part (safety run-in, dose escalation, dose expansion) •DS-8201 + durvalumab + cisplatin •DS-8201 + durvalumab + carboplatin •DS-8201 + durvalumab + pemetrexed •DS-8201 + durvalumab	Primary endpoint: Safety Secondary endpoint: ORR, DOR, DCR, PFS, OS, PK, etc.	EU/Asia	FPD: Nov 2021
Phase 3 DESTINY-Lung04  NCT05048797 jRCT2011210058  AstraZeneca	NSCLC with HER2 exon 19 or exon 20 mutation, 1L	264	Randomized, open label •DS-8201 •pemetrexed + pembrolizumab + cisplatin or carboplatin	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, safety, PK, etc.	JP/US/EU /Asia	FPD: Dec 2021

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-Lung05  NCT05246514  AstraZeneca	NSCLC with HER2 exon 19 or exon 20 mutation, 2L or later	66	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, PFS, OS, PK, ADA, safety	China	FPD: FY2022 H1
Phase 2 HUDSON  NCT03334617  AstraZeneca	NSCLC, 2L or later	420	Non-randomized, open label, combination with durvalumab •DS-8201 + durvalumab  * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: ORR Secondary endpoint: DCR, best percentage change in tumor size, DOR, PFS, OS	US/EU /Asia	FPD: Jun 2020
Phase 2 DESTINY-CRC01  NCT03384940 JapicCTI-173808  AstraZeneca	HER2 expressing colorectal cancer, 3L	90	Non-randomized, open label •DS-8201	Primary endpoint: ORR Secondary endpoint: PFS, OS, DOR, DCR, ORR, PK	JP/US/EU	FPD: Mar 2018 Study completed: Nov 2020
Phase 2 DESTINY-CRC02  NCT04744831 jRCT2051200124  AstraZeneca	HER2 overexpressing colorectal cancer, 3L	120	Randomized, double blind •DS-8201 : 6.4mg/kg •DS-8201 : 5.4mg/kg	Primary endpoint: ORR Secondary endpoint: DOR, DCR, PFS, OS, PK, PRO, safety	JP/US/EU /Asia	FPD: Mar 2021
Phase 2 DESTINY-PanTumor01  NCT04639219 jRCT2031210132  AstraZeneca	HER2 mutated tumors (e.g. colorectal cancer, urothelial cancer, gastric cancer, hepatobiliary cancer, endometrial cancer, melanoma, ovarian cancer, cervical cancer, salivary gland cancer, pancreatic cancer, breast cancer)	100	Open label •DS-8201	Primary endpoint: ORR Secondary endpoint: DOR, DCR, PFS, ORR, OS, safety, PK	JP/US/EU /Asia	FPD: Jan 2021

## Trastuzumab deruxtecan/DS-8201/T-DXd (HER2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 DESTINY-PanTumor02 NCT04482309 AstraZeneca	HER2 expressing tumors (bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, rare tumors)	280	Non-randomized •DS-8201	Primary endpoint: ORR Secondary endpoint: DOR, DCR, PFS, OS, safety, PK, ADA	US/EU /Asia	FPD: Oct 2020
Phase 1 NCT03523572 BMS	HER2 positive/low breast cancer HER2 positive/low urothelial carcinoma	99	Non-randomized, open label, combination with nivolumab, two-part (dose escalation, dose expansion) •DS-8201 + nivolumab	Primary endpoint: ORR, safety Secondary endpoint: DOR, DCR, PFS, OS, ORR	US/EU	FPD: Aug 2018
Phase 1 NCT04042701 Merck	HER2 positive/low breast cancer HER2 expressing/mutated NSCLC	115	Non-randomized, open label, combination with pembrolizumab •DS-8201 + pembrolizumab	Primary endpoint: Safety, ORR Secondary endpoint: DOR, DCR, PFS, TTR, OS	US/EU	FPD: Apr 2020
Phase 1/2a PETRA NCT04644068 AstraZeneca	Solid tumors	715	Non-randomized, open label, combination with AZD5305 •DS-8201 + AZD5305	Primary endpoint: Safety Secondary endpoint: Tumor size change, ORR, DOR, PFS, TTR, PK, ADA, etc	US/EU /Asia	

## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Antibody-drug conjugate which is composed of a humanized monoclonal antibody specifically targeting TROP2 (Research collaboration with Sapporo Medical University). TROP2 is an antigen highly expressed on the cell membrane of cancer cells, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 4.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 TROPION- PanTumor01  NCT03401385 JapicCTI-173812  AstraZeneca	NSCLC TNBC HR positive breast cancer SCLC Transitional cell carcinoma of the urothelium HER2 negative gastroesophageal cancer Esophageal cancer, etc.	770	Open label, two-part (dose escalation, dose expansion) •DS-1062	Primary endpoint: Safety Secondary endpoint: PK, ADA	JP/US	FPD: Feb 2018
Phase 1/2 TROPION- PanTumor02  NCT05460273  AstraZeneca	NSCLC TNBC	118	Open label •DS-1062	Primary endpoint: ORR Secondary endpoint: ORR, DOR, DCR, BOR, TTR, PFS, OS, safety, PK, etc.	China	FPD: Jul 2022
Phase 3 TROPION-Lung01  NCT04656652 jRCT2071200104  AstraZeneca	NSCLC, 2L/3L	590	Randomized, open label •DS-1062 •Docetaxel	Primary endpoint: PFS, OS Secondary endpoint: ORR, DOR, TTR, DCR, safety, PK, ADA	JP/US/EU /Asia	FPD: Feb 2021
Phase 1 TROPION-Lung02  NCT04526691 jRCT2031200193  Merck AstraZeneca	NSCLC (without actionable mutation) Part1: 3L or later Part2: 1L/2L	120	Open label, combination with pembrolizumab, two-part (dose escalation, dose expansion) •DS-1062 + pembrolizumab ± platinum chemotherapy	Primary endpoint: Safety and tolerability Secondary endpoint: ORR, DOR, PFS, OS, PK, ADA	JP/US/EU /Asia	FPD: Oct 2020



## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 TROPION-Lung04  NCT04612751 jRCT2031200449  AstraZeneca	NSCLC (without actionable mutation), 1L/2L	68	Open label, combination with durvalumab, two-part (dose escalation, dose expansion) •DS-1062 + durvalumab ± carboplatin	Primary endpoint: Safety and tolerability Secondary endpoint: ORR, DOR, PFS, OS, PK, ADA	JP/US/EU	FPD: Mar 2021
Phase 2 TROPION-Lung05  NCT04484142 jRCT2041200097  AstraZeneca	NSCLC (with actionable mutation)	150	Open label •DS-1062	Primary endpoint: ORR Secondary endpoint: DOR, PFS, OS, safety, PK	JP/US/EU /Asia	FPD: Mar 2021
Phase 3 TROPION-Lung08  NCT05215340 jRCT2061210074  Merck AstraZeneca	NSCLC (without actionable mutation and PD-L1 ≥50%), 1L	740	Randomized, open label •DS-1062 + pembrolizumab •Pembrolizumab	Primary endpoint: PFS, OS Secondary endpoint: ORR, PFS, DOR, TTR, DCR, Time to deterioration (TTD), safety, ADA, etc.	JP/US/EU /Asia	FPD: Mar 2022
Phase 1b/2 BEGONIA  NCT03742102  AstraZeneca	TNBC, 1L	200	Non-randomized, open label, combination with durvalumab •DS-1062 + durvalumab  * Umbrella study of durvalumab led by AstraZeneca	Primary endpoint: Safety Secondary endpoint: ORR, PFS, DOR, OS, PK	US/EU /Asia	FPD: May 2021
Phase 3 TROPION-Breast01  NCT05104866 jRCT2031210440  AstraZeneca	HR positive/HER2 negative breast cancer, 2L/3L	700	Randomized, open label •DS-1062 * Physician's choice (capecitabine, gemcitabine, eribulin or vinorelbine)	Primary endpoint: PFS, OS Secondary endpoint: ORR, DOR, PFS, DCR, PK, ADA, etc	JP/US/EU /Asia	FPD: Nov 2021
Phase 3 TROPION-Breast02  NCT05374512 jRCT2061220029  AstraZeneca	TNBC, 1L	600	Randomized, open label •DS-1062 * Physician's choice (paclitaxel, nab-paclitaxel, carboplatin, capecitabine, eribulin)	Primary endpoint: PFS, OS Secondary endpoint: ORR, DOR, PFS, PK, ADA, safety, etc	JP/US/EU /Asia	FPD: Jun 2022

## Datopotamab deruxtecan/DS-1062/Dato-DXd (TROP2-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2a PETRA  NCT04644068  AstraZeneca	Solid tumors	715	Non-randomized, open label •DS-1062 + AZD5305	Primary endpoint: Safety Secondary endpoint: Tumor size change, ORR, DOR, PFS, TTR, PK, ADA, etc	JP/US/EU /Asia	FPD: Mar 2022
Phase 2 ORCHARD  NCT03944772  AstraZeneca	EGFR mutated NSCLC, 2L	210	Non-randomized, open label •DS-1062 + osimertinib	Primary endpoint: ORR Secondary endpoint: PFS, DOR, OS, PK, safety, etc.	JP/US/EU /Asia	FPD: FY2022 Q2

## Patritumab deruxtecan/U3-1402/HER3-DXd (HER3-directed ADC)

Antibody-drug conjugate which is composed of fully human monoclonal antibody specifically targeting HER3, one of the Epidermal Growth Factor Receptor (EGFR) family proteins, and a covalently linked drug (payload) via a cleavable linker. Payload is a potent and membrane permeable DNA topoisomerase I inhibitor which enables elimination of both target tumor cells and the surrounding tumor cells. Drug-to-antibody ratio is approximately 8.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT02980341 JapicCTI-163401	Breast cancer	184	Randomized, open label, two-part (dose escalation, dose expansion) •U3-1402	Primary endpoint: Safety, antitumor effect Secondary endpoint: PK	JP/US	FPD: Dec 2016
Phase 1 NCT03260491 JapicCTI-194868	NSCLC	264	Non-randomized, open label, two-part (dose escalation, dose expansion) •U3-1402	Primary endpoint: Safety, ORR Secondary endpoint: PK, ORR, DCR, DOR, TTR, PFS, OS, safety	JP/US/EU /Asia	FPD: Feb 2018
Phase 2 HERTHENA-Lung01 NCT04619004 jRCT2031200186	EGFR mutated NSCLC, 3L	420	Randomized, open label •U3-1402	Primary endpoint: ORR Secondary endpoint: DOR, PFS, ORR, DCR, TTR, OS, safety	JP/US/EU /Asia	FPD: Feb 2021  Dec 2021: Breakthrough Therapy Designation (US)
Phase 1 NCT04676477 jRCT2031200247  AstraZeneca	EGFR mutated NSCLC, 1/2L	252	Non-randomized, open label, two-part (dose escalation, dose expansion) •U3-1402 + Osimertinib	Primary endpoint: Safety, ORR Secondary endpoint: ORR, DOR, DCR, TTR, PFS, OS, safety, PK, etc.	JP/US	FPD: Jun 2021
Phase 3 prep HERTHENA-Lung02 NCT05338970 jRCT2021220002	EGFR mutated NSCLC, 2L	560	Randomized, open label, active control •U3-1402 •Platinum-based chemotherapy	Primary endpoint: PFS Secondary endpoint: OS, PFS, ORR, DOR, CBR, DCR, safety, etc.	JP/US/EU /Asia	FPD planned: FY2022 H1

## ◆ Alpha (Oncology Late-Stage Pipeline Products)

### Quizartinib/AC220 (FLT3 inhibitor)

Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring FLT3-ITD mutation is expected.

Brand name: VANFLYTA (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 QuANTUM-R  NCT02039726	AML, relapsed/refractory	367	Randomized, open label, active-controlled •Quizartinib •Chemotherapy	Primary endpoint: OS Secondary endpoint: EFS	JP/US/EU /Asia	FPD: May 2014 TLR: May 2018  Jun 2019: Received CRL (US) Oct 2019: Launch (JP) Oct 2019: Received negative CHMP opinion (EU)  Mar 2009: Orphan Drug Designation (US/EU)
Phase 3 QuANTUM-First  NCT02668653 JapicCTI-173667	AML, 1L	539	Randomized, double-blind, placebo-controlled •Quizartinib + chemotherapy •Placebo + chemotherapy	Primary endpoint: OS Secondary endpoint: EFS, etc.	JP/US/EU /Asia	FPD: Sep 2016 TLR: Nov 2021  Mar 2009: Orphan Drug Designation (US/EU)

## Pexidartinib/PLX3397 (CSF-1/KIT/FLT3 inhibitor)

The molecular-targeted agent to inhibit CSF-1R, KIT and FLT3. This agent is expected to reduce tumor cell proliferation and expansion of metastases.

Brand name: TURALIO (US)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 NCT04488822	Tenosynovial giant cell tumor	35	Open label •Pexidartinib	Primary endpoint: ORR Secondary endpoint: TVS, ROM, PROMIS, DOR, etc.	Asia	FPD: Sep 2020
Phase 2 NCT04703322 jRCT2041200074	Tenosynovial giant cell tumor	21	Open label •Pexidartinib	Primary endpoint: Safety, PK, ORR Secondary endpoint: Safety, TVS, ROM, PROMIS, DOR, etc.	JP	FPD: Apr 2021

## Valemetostat/DS-3201 (EZH1/2 inhibitor)

Inhibitor of histone methylases, EZH1 and EZH2. Some cancer cells grow dependently on these enzymes.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 (pivotal) NCT04102150 JapicCTI-194964	Adult T-cell leukemia/lymphoma	25	Open label •DS-3201	Primary endpoint: ORR Secondary endpoint: ORR, CR rate, TTR, DOR, PFS, OS, etc.	JP	FPD: Dec 2019 TLR: Jul 2021 Submission: Dec 2021  Nov 2021: Orphan Drug Designation
Phase 2 (pivotal) VALENTINE-PTCL01 NCT04703192 jRCT2071200095	Relapsed/refractory peripheral T-cell lymphoma	176	Non-Randomized, open label •DS-3201	Primary endpoint: ORR Secondary endpoint: DOR, CR rate, safety, etc.	JP/US/EU /Asia	FPD: Jun 2021  Apr 2019: SAKIGAKE Designation (JP) Dec 2021: Orphan Drug Designation (US)
Phase 2 NCT04842877 LYSA	Relapsed/refractory B-cell lymphoma	141	Non-Randomized, open label •DS-3201	Primary endpoint: ORR Secondary endpoint: CR rate, PFS, DOR, TTR, safety, PK	EU	FPD: Jun 2021
Phase 1 NCT02732275 JapicCTI-163173	Non-Hodgkin's lymphomas	100	Open label •DS-3201	Primary endpoint: Safety, PK, antitumor effect Secondary endpoint: ORR, DCR, DOR, PFS, etc.	JP/US	FPD: Apr 2016

## ◆ Alpha (Oncology Early-Stage Pipeline Products)

### DS-1001 (Mutant IDH1 inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT03030066 JapicCTI-163479	Glioma	47	Open label •DS-1001	Primary endpoint: Safety Secondary endpoint: Safety, PK, antitumor effect	JP	FPD: Jan 2017
Phase 2 NCT04458272 JapicCTI-205339	Glioma	25	Open label •DS-1001	Primary endpoint: ORR, safety Secondary endpoint: antitumor effect, TTR, DOR, PFS, OS, PK, etc	JP	FPD: Jul 2020

### PLX2853 (BET inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT03787498	Relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome	22	Open label •PLX2853	Primary endpoint: Safety, PK Secondary endpoint: OCR, ORR, DOR, EFS, PFS, OS	US	FPD: Mar 2019
Phase 1 NCT03297424	Advanced malignancies	166	Open label •PLX2853	Primary endpoint: Safety, PK, antitumor effect Secondary endpoint: ORR, DOR, PFS, OS	US	FPD: Sep 2017
Phase 1b/2a NCT04493619	Gynecologic neoplasms Epithelial ovarian cancer	67	Non-randomized, open label •PLX2853 + carboplatin	Primary endpoint: ORR, MTD, RP2D Secondary endpoint: Safety, DOR, DCR, PFS, OS, PK	US	FPD: Aug 2020
Phase 1/2 NCT04556617	Prostate cancer	110	Non-randomized, open label •PLX2853 + abiraterone acetate + prednisone •PLX2853 + olaparib	Primary endpoint: ORR, safety Secondary endpoint: PFS, OS, PK, etc.	US	FPD: Sep 2020

## DS-7300 (B7-H3-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT04145622 JapicCTI-194992	Esophageal squamous cell carcinoma, castration-resistant prostate cancer, sq-NSCLC etc.	205	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-7300	Primary endpoint: Safety, antitumor effect Secondary endpoint: PK, etc.	JP/US	FPD: Oct 2019
Phase 2 NCT05280470 jRCT2041220019	Extensive-stage SCLC, 2L+	80	Randomized, open label •DS-7300 : 8mg/kg •DS-7300 : 12mg/kg	Primary endpoint: ORR Secondary endpoint: Safety, PFS, DOR, OS, TTR, ORR, DCR, PK, ADA	JP/US/EU /Asia	FPD: Jun 2022

## DS-1055 (anti-GARP antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04419532 JapicCTI-205292	Solid tumors	40	Non-randomized, open label •DS-1055	Primary endpoint: Safety Secondary endpoint: PK, ADA, etc.	JP/US	FPD: Oct 2020

## DS-6000 (CDH6-directed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04707248 jRCT2031220075	Renal cell carcinoma, ovarian cancer	102	Non-randomized, open label, two-part (dose escalation, dose expansion) •DS-6000	Primary endpoint: Safety Secondary endpoint: PK, ORR, DOR, DCR, etc.	US/JP	FPD: Jan 2021

## DS-1594 (Menin-MLL binding inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT04752163 MD Anderson	Acute myeloid leukemia, acute lymphoblastic leukemia	122	Non-randomized, open label •DS-1594 •DS-1594 + venetoclax + azacitidine •DS-1594 + mini HCVD •DS-1594 + posaconazol or voriconazole	Primary endpoint: Safety, CR rate Secondary endpoint: CR rate, MLFS rate, PR rate, ORR, DOR, EFS, OS, mortality rate, etc.	US	FPD: Apr 2021

## DS-9606 (Target undisclosed ADC)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT05394675	Solid tumors	125	Non-randomized, open label •DS-9606	Primary endpoint: Safety, ORR Secondary endpoint: PK, DOR, DCR, TTR, PFS, ADA, etc.	US/EU	FPD: Jun 2022



## ◆ Alpha (Specialty Medicines Late-Stage Pipeline Products)

### Mirogabalin/DS-5565 ( $\alpha_2\delta$ ligands)

The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.

Brand name: TARLIGE (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 NCT03901352 JapicCTI-194653	Central neuropathic pain	300	Randomized, double-blind, placebo-controlled •Mirogabalin •Placebo	Primary endpoint: average daily pain score Secondary endpoint: visual analogue scale, average daily sleep interference score	JP/Asia	FPD: Mar 2019 TLR: Dec 2020 Submission: May 2021 Approval: Mar 2022
Phase 3 NCT04094662	Diabetic peripheral neuropathic pain	360	Randomized, double-blind, placebo-controlled •Mirogabalin •Placebo	Primary endpoint: average daily pain score Secondary endpoint: visual analogue scale, average daily sleep interference score	China	FPD: Sep 2019

## Esaxerenone/CS-3150 (MR blocker)

The agent inhibits aldosterone binding to Mineralocorticoid Receptor (MR) which stimulate the sodium absorption into kidney. This agent is expected to exhibit antihypertensive and organ-protective effect.

Brand name: MINNEBRO (JP)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 JapicCTI-173695 Exelixis, Inc.	Diabetic nephropathy	400	Randomized, double-blind, placebo-controlled •Esaxerenone •Placebo	Primary endpoint: UACR remission rate Secondary endpoint: change rate in UACR and eGFR, etc.	JP	FPD: Sep 2017 TLR: Jul 2019

## Alpha (Specialty Medicines Early-Stage Pipeline Products)

### Renadirsen Sodium/DS-5141 (ENA-oligonucleotides)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT02667483 JapicCTI-153072 ODTI	Duchenne muscular dystrophy	8	Open label •DS-5141	Primary endpoint: Safety, PK, dystrophin protein expression in muscle tissue Secondary endpoint: production of exon 45-skipped dystrophin mRNA in muscle tissue	JP	FPD: Oct 2015 TLR: Dec 2020  Apr 2017: SAKIGAKE Designation Apr 2018: announced TLR of 12-week treatment study Jun 2021: announced TLR of 48-week treatment study
Phase 2 NCT04433234 JapicCTI-205321	Duchenne muscular dystrophy	8	Long-term study of above phase 1/2 study •DS-5141	Endpoint: Safety, motor function, respiratory function, cardiac function, quantitative muscle strength evaluation, PK	JP	

### DS-1211 (TNAP inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 2 prep	Pseudoxanthoma elasticum				US	SAD and MAD studies completed

### DS-6016 (anti-ALK2 antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04818398 jRCT2051200155	Healthy volunteers, fibrodysplasia ossificans progressiva	48	Randomized, double-blind, placebo-controlled	Primary endpoint: Safety Secondary endpoint: PK	JP	FSD: Apr 2021

## DS-7011 (anti-TLR7 antibody)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT05203692	Healthy volunteers, systemic lupus erythematosus	80	Randomized, double-blind, placebo-controlled	Primary endpoint: Safety Secondary endpoint: PK, PD, Immunogenicity	US	FSD: Feb 2022

## DS-2325 (KLK5 inhibitor)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT05388903	Healthy volunteers, Netherton syndrome	64	Randomized, double-blind, placebo-controlled	Primary endpoint: Safety Secondary endpoint: PK, ADA, etc.	US	FSD: Jun 2022

## Alpha (Vaccine)

### VN-0107/MEDI3250 (live attenuated influenza vaccine)

The US brand name of this vaccine is FluMist Quadrivalent that is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 JapicCTI-163400 AstraZeneca/ MedImmune	Prevention of seasonal influenza	782	Randomized, double-blind, placebo-controlled •VN-0107 •Placebo	Primary endpoint: onset of influenza, safety Secondary endpoint: onset of influenza	JP	Jun 2016: Submission by Daiichi Sankyo

### VN-0102/JVC-001 (mixed measles-mumps-rubella vaccines)

Trivalent mixed vaccine (MMR vaccine) containing three attenuated viruses of measles, mumps and rubella, which has not been approved in Japan.

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 3 JapicCTI-205118	Prevention of measles, mumps and rubella in healthy Japanese children aged 12 months or more and less than 24 months	840	Randomized, double-blind, active-controlled •VN-0102/JVC-001 •Dry Live Attenuated Measles Rubella vaccine, Freeze-dried Live Attenuated Mumps vaccine	Primary endpoint: Seroprotection rates for measles, mumps and rubella Secondary endpoint: Seroconversion rates for measles, mumps, and rubella	JP	FSD: Feb 2020 LSD: Sep 2020

## DS-5670 (COVID-19 mRNA vaccines)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1/2 NCT04821674 jRCT2071200110	Healthy adults and elderly, prevention of COVID-19	152	Randomized, double-blind, placebo-controlled •DS-5670 •Placebo	Primary endpoint: Safety, immunogenicity (neurralizing activity) Secondary endpoint: immunogenicity, PK	JP	FSD: Mar 2021
Phase 2 jRCT2071210086	Healthy adults, prevention of COVID-19	80	Randomized, double-blind, uncontrolled	Primary endpoint: Safety Secondary endpoint: Immunogenicity	JP	FSD: Nov 2021
Phase 1/2/3 jRCT2071210106	Healthy adults who have completed initial vaccination of approved COVID-19 vaccine, prevention of COVID-19	5,028	Randomized, single-blind, active-controlled, two-part (dose confirmation study and non-inferiority study) •DS-5670 •Comirnaty •Spikevax	Primary endpoint: Immunogenicity (Geometric mean fold rise of neutralizing activity), safety Secondary endpoint: Immunogenicity, safety	JP	FSD: Jan 2022 TLR planned: FY2022 H2

## VN-0200 (RS virus vaccines)

Study Name	Population	Sample Size	Study Design	Evaluation Items	Region	Status
Phase 1 NCT04914520 jRCT2031210069	Health adults and elderly, prevention of respiratory syncytial (RS) virus infection	48	Randomized, double-blind, placebo-controlled •VN-0200 •Placebo	Primary endpoint: Safety, tolerability Secondary endpoint: immunogenicity	JP	FSD: Jun 2021

◆ **Stage-up Projects (Major Changes from the FY2021 Q4 Financial Announcement in April 2022)**

Generic Name/Project Code Number Mechanism of action	Target Indication	Current Stage	Note
Trastuzumab deruxtecan/DS-8201/T-DXd HER2-directed ADC	HER2 positive breast cancer, 2L	Approved	US/EU, DESTINY-Breast03
Trastuzumab deruxtecan/DS-8201/T-DXd HER2-directed ADC	HER2 low breast cancer, post chemotherapy	Filed	US/EU/JP, DESTINY-Breast04
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	TNBC, 1L	Ph3	US/EU/JP/Asia, TROPION-Breast02
DS-7300 B7-H3 directed ADC	Extensive-stage SCLC, 2L or later	Ph2	US/EU/JP/Asia
Datopotamab deruxtecan/DS-1062/Dato-DXd TROP2-directed ADC	NSCLC, TNBC	Ph1/2	TROPION-PanTumor02, China
DS-9606 Target undisclosed ADC	Solid tumors	Ph1	US/EU
DS-2325 KLK5 inhibitor	Netherton syndrome	Ph1	US